ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon
MD and CEO, Richard Carreon
Source: ImpediMed
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ImpediMed (IPD) partners with Icon Group to establish lymphoedema screening services for breast cancer patients across Australia and New Zealand
  • The partners have agreed to roll out 13 of IPD’s SOZO units at Icon centres
  • SOZO is a digitally connected health platform that monitors patient testing in real time and can help in the early detection of lymphoedema
  • IPD is expanding its corporate accounts across the Asia Pacific and US
  • Shares are trading flat at 12 cents each at 12:38 pm AEST

ImpediMed (IPD) has partnered with Icon Group to establish lymphoedema screening services for breast cancer patients across Australia and New Zealand.

Icon is reportedly Australia’s largest dedicated cancer care provider, with 31 cancer centres in Australia and a presence across oncology hospitals and radiation facilities in New Zealand, Singapore, Hong Kong and mainland China.

Together, the companies will roll out 13 SOZO units — a digitally connected health platform that enables IPD to see patient testing in real time, anywhere in the world.

In recent months, ImpediMed said it had identified a deep pipeline of opportunities across the Asia Pacific and US markets as large hospital systems seek to improve patient care and grow within a COVID-19 environment.

Icon Group CEO Mark Middleton said the provision of lymphoedema screening at 13 Icon centres would help cancer patients take control from the start of their journey.

“SOZO facilitates the identification of each patient’s individual risk of developing lymphoedema, ensuring the early detection of lymphoedema and the delivery of appropriate education and management to reduce its progression,” he said.

“At a time when there are so many uncertainties for a patient, this service arms them with important knowledge to manage their wellbeing throughout surgery, treatment and beyond.”

ImpediMed Managing Director and CEO Richard Carreon also commented on the deal.

“We are proud to work with providers like Icon who strive for the highest levels of care for patients undergoing cancer treatment,” he said.

“This agreement opens the door to thousands of patients to participate in a state-of-the-art lymphoedema prevention program aimed at stopping chronic lymphoedema before it starts”.

Mr Carreon said he believed the Icon contract to be the first of many expansions led by the company’s corporate accounts team.

Shares were trading flat at 12 cents each at 12:38 pm AEST.

IPD by the numbers
More From The Market Herald
The Market Herald Video

" PainChek (ASX:PCK) to receive govt funding for children’s disability app

PainChek (ASX:PCK) has been awarded a $392,820 grant from the Western Australia State Government's Future Health…
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform

Prescient Therapeutics (ASX:PTX) has been granted a key US patent for its OmniCAR universal immune receptor…

" Antisense Therapeutics (ASX:ANP) dosing of muscular dystrophy drug on hold

Antisense Therapeutics (ASX:ANP) applies for partial clinical hold that limits dosing of its drug for muscular…
Antisense Therapeutics (ASX:ANP) - MD and CEO, Mark Diamond

" Antisense Therapeutics (ASX:ANP) to present new data

Antisense Therapeutics (ASX:ANP) announces its new proteomics data will be presented in a virtual congress.